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Systematic reviewa b s t r a c t
Background: The treatment approach for aggressive fibromatosis is changing. Although surgery is the
mainstay in common practice, recent literature is reporting a more conservative approach. We compared
the local control rate for surgery, surgery with radiotherapy, radiotherapy alone and a wait and see policy
in a systematic review.
Methods: A comprehensive search of the databases PubMed/Medline, Embase and Cochrane, of the med-
ical literature published in 1999 till March 2017 was performed by two reviewers, including articles
about extra abdominal aggressive fibromatosis without the genetical variants. A total of 671 studies were
assessed for eligibility, and 37 studies were included for analysis, representing 2780 patients.
Results: The local control rates for surgery alone, surgery and radiotherapy, radiotherapy alone and
observation were 75%, 78%, 85% and 78%, respectively. For patients with recurrent disease observation
had a better local control rate than surgery alone (p = 0.001). In the observation group, stabilization of
the tumor was seen in median 14 (range 12–35) months. The time to local recurrence in the treatment
group was median 17 (range, 11–52) months.
Conclusion: A watchful conservative first line approach with just observation and closely monitoring, by
means of physical examination and MRI, appears to be justified in a subgroup of patients without clinical
symptoms and no possible health hazards if the tumor would progress.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Although aggressive fibromatosis (AF) is histological classified
as a low grade soft tissue sarcoma it can clinically lead to severe
morbidity, functional impairment and even death when located
at anatomical critical sites. The treatment approach has changed
over time: surgery remained the mainstay in the treatment of AF,
but other treatment modalities were explored. Due to the infiltra-
tive pattern and the lack of a pseudocapsule, clear margins are dif-
ficult to obtain, necessitating repeated operations and causing
severe cosmetic and functional morbidity. Moreover, surgery itself
can evoke recurrent disease as trauma is a known predictive factor
in the development of AF [1]. In the nineties, adjuvant radiotherapy
was successfully applied to improve local control [2]. Radiotherapy
alone was performed in selected cases, usually in patients withunresectable tumors, leading in some cases to local control or even
regression [3,4]. Systemic treatment has been reported as an effec-
tive treatment in some studies, albeit the number of patients in
these studies was low and optimal drug doses and treatment dura-
tion remain unclear [5]. More recently, a wait-and-see policy has
been advocated because AF has the potential to regress sponta-
neously [6].
Since AF has a low mortality and usually occurs in young
patients, treatment morbidity in the short and long term is an
important factor in the treatment decision. Due to the low inci-
dence of AF, studies usually concern small number of patients,
therefore we aimed to analyze outcome for different treatment
strategies in a systematic review.Material and method
A comprehensive computer-aided search of the databases
PubMed/Medline, Embase and Cochrane, of medical literature pub-
lished after 1998, was conducted in March 2017 using the search
2 J.M. Seinen et al. / Clinical and Translational Radiation Oncology 12 (2018) 1–7term in Pubmed/Medline was: ‘(desmoid[All Fields] OR aggressive
fibromatosis[All Fields]) AND surgery[All Fields] AND English[Lan-
guage] NOT case report[All Fields] Not polyposis[Title Word] NOT
pediatric[All Fields]’ (in which surgery was replaced by ‘radiother-
apy’ and ‘wait and see’). The search term in Embase was: ‘‘desmoid
tumor”/exp AND surgery AND [english]/lim AND [1–1–1999]/sd
NOT [01–3–2017]/sd NOT ‘case report’/exp NOT polyposis’ (in
which surgery was replaced by ‘radiotherapy’ and ‘wait and see’).
The search term in Cochrane: ‘Desmoid’. We augmented our com-
puterised literature search by manually reviewing the reference
lists of identified studies and relevant reviews. Two reviewers
(JMS/MGN) independently selected studies for possible inclusion
in the review by checking titles. Criteria for inclusion were: clinical
studies evaluating one of the four treatment strategies in desmoid
tumors/aggressive fibromatosis: 1) surgery alone, 2) surgery with
adjuvant radiotherapy, 3) radiotherapy alone and 4) wait-and-see
policy. Criteria for exclusion were: studies about case reports,
reviews and editorials. Furthermore, we excluded all articles that
studied solely children, Gardner syndrome or familial polyposis
coli as subjects, because paediatric patients have a high recurrence
rate and often have a different treatment strategy, and because AF
in Gardner syndrome can be considered a different category due to
the genetic linkage. The articles related to one anatomic region
were also excluded because certain anatomic regions have their
own specific biological tumor behaviour [7].
The final decision regarding inclusion was based on the full arti-
cle. Two reviewers (JMS/MGN) independently assessed the eligibil-
ity of the studies. If there was any disagreement between the
readers, a consensus was reached by discussion.
In the surgical group, recurrent disease is described as recurrent
disease after complete resection. In the radiotherapy and observa-
tion group, recurrent disease would be described after completeFig. 1. Flow diagramregression, and progressive disease after partial regression or stabi-
lization of disease.Statistical methods
The Fisher exact test was used to assess the significance of dif-
ferences between local control rates of the different treatment
modalities. Local control was defined as no recurrence or no pro-
gression of disease. The 2-sided p value was used and was consid-
ered significant if p < 0.05. This data is available in the
Supplementary Table 1. The Fisher exact test is considered appro-
priate for independent observations; all articles describing the
same study populations were excluded.
Since the treatment modalities solely radiotherapy and obser-
vation do not include surgical margins, no comparison was made
within this subgroup (Supplementary Table 1). In addition, no sta-
tistical analysis of comparison was made in case the number of
patients was very small.Results
Literature search and data description
Using the search strategy, 671 studies were listed, of which 85
met the inclusion criteria based on the abstract. Finally, after read-
ing the full text, 37 studies were included in the analysis (Fig. 1)
[1,6–41].
The total amount of patients studied for surgery was 1670, for
surgery and adjuvant radiotherapy 815, for radiotherapy alone
155 and for observation 140 (Table 1). The median radiation dose
for the surgery and adjuvant radiotherapy group was 54 (3–74)literature search.
Table 1












Bonvalot S [7] 100 (primary) abd/chest wall (42), LE
(23), UE (7), HN (14),
trunk (14)
67 13 – – 50 (4–60) S + RT 76
Stoeckle E [8] 65/35 – 92 7 – – 50 (20–60) S + RT 123
El-Haddad [9] 48/52 E (52), trunk (39), HN
(9)
6 41 4 3 50.4 (45–60) S + RT 88
Husain Z [10] – LE (20), UE (40),
buttock (10), Trunk
(20), HN (10)
– 10 – – 50.7 (44–62) S + RT 48
Huang K [11] 75/25 abd wall (50), LE (18),
trunk (11), HN (18), UE
(3)
106 25 – – (45–55) S + RT 102
Ballo MT [12] 45/55 abd wall (10), HN (10),
trunk (44), buttock (5),
UE (18), LE (13)





Gronchi A [13] 63/27 abd wall (22), trunk
(50), LE (12), UE (8), HN
(8)
172 40 – – 57 (45–65) S + RT 135
Duggal A [14] 71/29 UE (34), LE (20), trunk
(31), abd wall (3),
buttock (12)
27 8 – – 50 (10–64) S + RT 68*
Gluck I [15] 76/24 trunk (57), E (13), HN
(20), abd/pelvis (10)




JelinekJA [16] – abd (17), E (83) 19 35 – – 54 S + RTa 38
Park HC [17] – E (36), HN (16), trunk
(32), buttocks (16)
– 21 3 – 48 (40–59) S + RT,
RT
39*
Lev D [18] 74/26 UE (14), LE (16), abd




94 35 9 – (50–56) S + RT,
RT
69
Phillips SR [19] 73/27 abd wall (21), HN (4),
trunk (42), UE (9), LE
(17) buttock (7)
73 – 2 18 (30–72) S + RT,
RT
63
Mankin HJ [20] – UE (7), LE (48), trunk
(34), abd wall/pelvis
(11)
185 39 – – – 31
Dalen BP [21] – abd wall (24), UE (22),
LE (22), trunk (31), HN
(1)
29 – 1 – – –
Zlotecki RA [22] 42/58 UE (42), LE (35), trunk
(7), abd (11), HN (5)
– 65c – 54 (50–56) S + RT,
RT
72
Barbier O [23] 42/58 UE (31), LE (58),
buttock (11)
– – – 26 – 16*
Baumert BG [24] 60/40 42 68 – 59 (3–74) S + RT 72
Fiore M[6] 65/35 E (33), trunk (17), HN
(4), abd wall (40), intra
abd (7)
– – – 83 – 33
Merchant NB [25] 100 (primary) E (49), trunk (23), abd
wall (20), HN(8)
74 31 – – (45–65) S + RTb 49
Nakayama T [26] 82/18 abd wall (18), UE (9),
HN (18), LE (46), trunk
(9)
2 – 9 – – 56
Pajaras B [27] 90/10 abd wall (45), intra abd
(15), UE (15), HN (10),
LE (10), trunk (5)
17 2 – – 50 (50) S + RT 35
Pignatti G [28] 42/58 UE (30), LE (60), trunk
(8), other (2)
63 17 0 1 (35–66) S + RT 134*
Schulz-Ertner D
[29]
43/57 HN (8), UE (25), LE (29),
abd wall (10), intra abd
(10), trunk (18)
– 26 2 – 48 (36–60) RTb 46
Sharma V [30] 88/12 E (45), HN (14), Trunk
(14), abd (27)





Shido Y [31] – trunk (30), UE (13), LE
+ buttock (57)
30 – – – – 89
Sorensen A [32] – abd(30), extra abd (70) 44 28 – – – 96
Guney Y [33] – UE (29), LE (29), HN
(14), buttock (14),
trunk (14)





Rudiger HA [34] 59/41 UE (31), LE (43), trunk
(26)
– 17 17 – 50 (24–60) S + RT 51*
(continued on next page)













Chew C [35] 36/64 UE (43), LE (40), HN
(17)
– 40 1 1 – 150
Kriz [36] 48/52 E (54) trunk (38) abd
wall (8)





Zeng [1] 67/33 abd wall (27) intra abd
(11) trunk (18) E (14)
HN (25) buttock (4)
184 39 – – 38–66 S + RT 54
Prodinger [37] UE (49) LE (51) 10 17 – – 50–60 S + RT 65
Shin [38] 74/26 trunk/HN (41) E (59) 95 24 – – 38–70 S + RT 82*
Sri ram [39] UE (10) HN (23) trunk
(18) buttock (14) LE
(35)
48 19 5 – 48
Keus [40] 61/39 UE (32) LE (32) HN (2)
trunk (23) abd wall
(11)
– – 44 – 56 RT 60
Ergen [41] 20/80 UE (20) LE (45) trunk
(20) intra abd (10) HN
(5)
– 18 2 – 60 (40–64) S + RT 77.5
RT = Radiotherapy, S = Surgery, FAP = Familial Adenomatous Polyposis FU: Follow-Up, E = extremity, LE = lower extremity, UE = upper extremity, HN = head and neck, abd =
abdominal.
a 5 patients received intra operative radiotherapy.
b Some patients received brachytherapy.
c Number of patients receiving S + RT and RT alone.
* Mean follow up.
Fig. 2. (A–C) Local controle rate stratisfied per subgroup.
4 J.M. Seinen et al. / Clinical and Translational Radiation Oncology 12 (2018) 1–7Gy, and for the radiotherapy alone group 50 (30–72) Gy. The med-
ian follow up was 63 (16–150) months.
Treatment results
The median age was 34 years. AF is more common among
women than men, ratio 2:1.
Analysing the amount of patients with local control in relation
to the total amount of patients per treatment group, the median
local control rates for surgery alone, surgery and radiotherapy,
radiotherapy alone and observation were 75%, 78%, 85% and 78%,
respectively.
The role of surgical margins
Within the surgical group radical resections (36%) were as com-
mon as marginal resections (35%), intralesional resections were
less common (11%).
As expected, local recurrence was more common after surgery
with positive margins compared to negative margins (Fig. 2A, Sup-
plementary Table 1). Adjuvant radiotherapy after positive margins
did not improve the local control rate (p = 0.549) [7–9,11,12,14,
15,17–19,21,24,26,28,30–33,35].
Between the treatment groups radiotherapy and observation,
irrespective of surgical margins, no significant difference existed
in terms of local control (p = 0.355).
The role of tumor status
Patients with recurrent disease had less local recurrences after
being treated with adjuvant radiotherapy compared to surgery
alone (p < 0.001) (Fig. 2B) [8,10,14,17,20,22,31,32]. Moreover,
patients who were being observed had a better local control
rate than patients treated with surgery alone (p = 0.001)
[8,14,20,23,26,31]. Similar results were seen when the observation
group was compared to the total surgical group with or without
adjuvant radiotherapy, although this did not reach statistical sig-
nificance (p = 0.063) [8,10,14,17,20,22,23,26,31,32]. For radiother-
apy alone the numbers were too small to perform statistical
analysis.
Table 2
Recurrence free survival of the different treatment modalities with respect to tumor size.
Surgery Surgery + Radiotherapy Radiotherapy Observation
5RFS 10RFS 5RFS 10RFS 5RFS 10RFS 5RFS 10RFS
<5 cm 94 60, 94 – 84 – 100 44, 52 –
5 cm 72 63, 66 – 69 – 68 60, 52 –
RFS = Recurrence free survival.
J.M. Seinen et al. / Clinical and Translational Radiation Oncology 12 (2018) 1–7 5The role of tumor location and size
Even though the percentage of patients with local control was
higher in the group of patients treated with adjuvant radiotherapy
for both tumors located at the extremities and other locations, this
did not reach statistical significance (p = 0.481 and p = 0.755,
respectively) (Fig. 2C) [10,14,17,21,22,26,32]. Regarding the radio-
therapy alone and the observation group numbers were too small
to analyse.
For analyzing tumor size, we used the recurrence free survival
instead of actual number of patients since more articles noted local
control rate this way. Tumors over 5 cm [13,26], had a worse recur-
rence free survival than smaller tumors, irrespective of treatment.
In the observation group no difference in five years recurrence free
survival was observed for tumor size [11] (Table 2).
Time to recurrence or stabilization of disease
The median time to local recurrence including all treatment
groups as noted in 15 articles was 17 (range, 11–52) months.
Two articles noted a mean recurrence time of 16 and 20 months.
For the observational treatment group, three studies described
the median time to stabilization of the tumor, which was 14
(range, 12–35) months. The median time to tumor growth in this
treatment group was 32 (range, 14–38) months.
Multivariate analysis
A multivariate analysis was performed in eight studies.
Prognostic factors predicting a negative outcome were large size
(>4 or 5 cm), tumor location (limb, other locations than abdominal
wall), positive surgical margins, deep seated tumors, age
(<30 years), surgical treatment without adjuvant radiotherapy,
recurrent disease and extracompartmentally situated tumors.
Complications and deaths due to treatment
In nine studies 14 patients were described who died of treat-
ment or disease related causes, which is <1% of all treated patients.
Since most articles did not describe the actual cause of death, it is
not certain if any patient died due to the tumor itself.Fig. 3. Treatment related complications in percentage.Fig. 3 describes the complications related to treatment. Soft tis-
sue defects ranged from light dermatitis, most commonly caused
by radiotherapy, to severe skin necrosis (in one case necessitating
admittance to the intensive care). Severe treatment related compli-
cations were described in four patients who developed a secondary
sarcoma (fibrosarcoma, angiosarcomas, MPNST) in the radiation
field.Discussion
In this systematic analysis we looked at the outcome of patients
treated with surgery with four different treatment strategies with
regard to local recurrence rates. Irrespective of treatment modality,
the local control rate was good, with over 75% local control in each
treatment group. This finding is in concordance with recently pub-
lished data [42].
Adjuvant radiotherapy is in many cases used to lower the risk of
local recurrence in case of positive margins. In this review, contrary
to previous findings of Nuyttens et al. [2] and Janssen et al. [42], no
significant advantage for adjuvant radiotherapy was observed
regarding local control [7,8,10,11,14,17,19,24,26,28,31,32,35].
There is however, a strong effect for adjuvant radiotherapy in
recurrent disease, comparatively to the results of Janssen et al.
[42]. An international survey in Europe showed that recurrences
after radiation tend to develop most commonly at the field border
or in areas receiving less than 50 Gy [24]. This implies wide field
margins and high radiation doses in order to achieve a better local
control rate. Although the radiation dose in this analysis varied,
most institutions used 50 Gy.
Recently the EORTC carried out a multicenter prospective phase
2 trial to determine the tumor response in patients with inoperable
aggressive fibromatosis using 56 Gy radiotherapy. Keus et al.
reported a good local control rate of 82% [40]. In the majority of
cases this meant partial regression (36%) or stabilized disease
(41%), only in a few cases complete regression (14%) of the tumor
was observed. Interestingly, even after three years response was
observed on MRI. Despite this good result, eventually 23% devel-
oped local progression, even after initial response. In two patients
treatment could not be continued due to extensive toxic effect of
radiation. The complication rate in Nuyttens et al. [2] was reported
in over one fifth of patients, and in Keus et al. [40] around one
third. Only a small percentage (5%) developed severe skin toxic
effects of grade 3/4 [40]. The link between the radiation dose and
the risk of local progression/recurrence is debated, but some argue
a better local control rate at high doses of 56 Gy [21]. However, the
incidence of complications increased parallel with the dose given.
Although the majority of complications is not severe and reversi-
ble, some severe complications including fractures and secondary
sarcomas occurred, which were also observed in this review. More
common complications were functional impairment and soft tissue
defects (70% of all complications), of which the latter was in most
cases reversible. The overall death rate is very low, with less than
1% of patients dying either due to the disease or treatment
complications.
Around ten years ago the first reports about a wait and see pol-
icy were published. Due to the fact that data are usually small due
to a relatively low incidence of AF, concerning 3% of all soft tissue
6 J.M. Seinen et al. / Clinical and Translational Radiation Oncology 12 (2018) 1–7sarcomas [43]. This analysis pooled data to determine whether or
not conservative treatment reaches acceptable local control rates
compared to surgical treatment. The majority of patients in this
analysis were still treated with surgery (surgical treatment
n = 2485 vs. non surgical treatment n = 295), with about one
sixth of institutions describing radiotherapy alone and/or
observation.
In most institutions a selection is performed for patient under-
going more conservative therapy. In case of radiotherapy alone,
patients usually had large tumors, or tumors in close adherence
to important structures that limited radical surgery [12,15,18,30].
Patients considered for observation usually had a tumor, that in
case of growth, was still eligible for surgery and had no major clin-
ical symptoms [6,7,19,23]. Only one study used a routinely first
line conservative approach for all patients presenting to the insti-
tution [6] with a relatively good local control rate of 65%. Of the
patients with primary disease, 35% had progressive disease, and
in 32% of these patients surgical treatment was finally necessary.
Interestingly, the progression free survival rate of patients with
primary tumors was 47% and with local recurrence 54%. Stabiliza-
tion of the tumor arose after a median time of >1 year after obser-
vation, and a local recurrence or progression occurred after a
median time of <3 years, which means that patients should be reg-
ularly observed within the first five years. If sudden progression
does develop, treatment should be re-evaluated.
Surprisingly, the treatment groups of radiotherapy alone and
observation had a relative similar local control rate as the surgery
group. One reason could be that surgery itself is a stimulant for
tumor growth. Interestingly, the radiotherapy alone group did
not have better local control rates than the observation group
(p = 0.355). It should be noted that there is a selection bias favour-
ing the observation group, due to the selection of tumors with a
less aggressive pattern. In addition, the follow up of the two largest
studies using primary observation was mean 16 months and
median 33 months, while the follow up of the largest studies with
radiotherapy only was median 56 months.
For primary tumors the local control rate did not seem to be
influenced by the choice of treatment. The opposite is true for
recurrent disease, in which adjuvant radiotherapy has a definite
advantage over surgery alone (p = 0.001). This could be explained
by the more aggressive nature of recurrent disease.
Based on this systematic review no preference of treatment
could be indicated based on tumor location (extremity vs other
locations), although outcome of patients with tumors located at
the extremities was worse. Especially patients with large tumors
located at the extremities have a worse local outcome, regardless
of the surgical margins [13].
Patients with a tumor size larger than 5 cm had a worse local
outcome, independent of the type of treatment except for the
observation group.
In addition to the variables mentioned in the previous section,
other studies that performed multivariate analysis showed that
deep seated tumors, age (<30 years) and extracompartmentally sit-
uated tumors were negative predicting markers of local outcome.
Similar predicting markers were also found in other soft tissue sar-
comas [35,44,45].
It is important to note that pooling of the data led to large sam-
ple sizes, however, when analyzing the subgroups, the sample sizes
diminished due to lack of reported data items. In addition, selec-
tion and reporting bias occurred due to the retrospective design
of most included studies.
Meta-analyses of the trial results were considered, but were
deemed not feasible because the heterogeneity of the patients,
tumor characteristics and interventions, were too great to allow
for pooling of data.Conclusion
With consideration of previously mentioned weaknesses of this
study and careful interpretation of the results, a watchful waiting
approach as a first line option could be justified, in addition with
closely monitoring by means of physical examination and MRI
during at least five years of follow up, in a subgroup of patients
without clinical symptoms and no possible health hazards if the
tumor would progress, and taking into account that a considerable
group of patients eventually does need surgical treatment.
More data is needed to confirm a conservative approach as a safe
treatment for AF, especially in smaller patient subgroups.
In case of recurrent disease, adjuvant radiotherapy with a dose
50 Gy has a definitive advantage over surgery alone. A multidis-
ciplinary sarcoma team should finally make the decision with
respect to the treatment options.
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